Viatris Inc (VTRS)
Pretax margin
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Earnings before tax but after interest (EBT) (ttm) | US$ in thousands | 202,900 | 2,005,500 | 2,216,100 | 2,439,300 | 2,813,200 | 1,661,700 | 1,248,800 | 473,500 | -664,400 | -1,058,100 | -1,016,400 | -777,300 | -200,800 |
Revenue (ttm) | US$ in thousands | 15,426,900 | 15,465,600 | 15,601,900 | 15,800,100 | 16,262,700 | 16,728,300 | 17,186,700 | 17,647,700 | 17,886,300 | 17,168,200 | 15,603,700 | 13,757,100 | 12,518,600 |
Pretax margin | 1.32% | 12.97% | 14.20% | 15.44% | 17.30% | 9.93% | 7.27% | 2.68% | -3.71% | -6.16% | -6.51% | -5.65% | -1.60% |
December 31, 2023 calculation
Pretax margin = EBT (ttm) ÷ Revenue (ttm)
= $202,900K ÷ $15,426,900K
= 1.32%
The pretax margin of Viatris Inc has varied significantly over the past eight quarters. In Q4 2023, the pretax margin dropped to 1.32%, a substantial decrease from the previous quarter's 16.34%. This decline may raise concerns about the company's ability to generate profits before accounting for taxes and other expenses. Comparing to the same period last year, Q4 2022's pretax margin was higher at 17.30%.
Overall, it is crucial for Viatris Inc to closely monitor and potentially address the factors contributing to the decline in pretax margin to ensure sustainable profitability in the future.
Peer comparison
Dec 31, 2023
Company name
Symbol
Pretax margin
Viatris Inc
VTRS
1.32%
Abbott Laboratories
ABT
16.90%
AbbVie Inc
ABBV
11.49%
Alkermes Plc
ALKS
19.22%
Amphastar P
AMPH
26.28%
ANI Pharmaceuticals Inc
ANIP
4.37%
Arcus Biosciences Inc
RCUS
-257.26%
Biomarin Pharmaceutical Inc
BMRN
9.72%
Bristol-Myers Squibb Company
BMY
18.72%
Catalent Inc
CTLT
-7.85%
Catalyst Pharmaceuticals Inc
CPRX
23.73%